Soleno Therapeutics will join Russell 3000 Index, showcasing progress with rare disease therapeutics
From GlobeNewswire: 2024-06-04 08:00:00
Soleno Therapeutics, Inc. announced it will join the Russell 3000 Index, reflecting progress with DCCR tablets for rare diseases. The Russell indexes reconstitution, capturing the largest US stocks by market capitalization, will include Soleno effective July 1, 2024. Investment managers utilize Russell indexes as benchmarks, with $10.5 trillion in assets benchmarked against them. Soleno focuses on rare disease therapeutics, with DCCR tablets targeting Prader-Willi syndrome. FTSE Russell provides benchmarking, analytics, and data solutions for investors globally, with FTSE Russell wholly owned by London Stock Exchange Group.
Soleno Therapeutics, Inc. is set to join the Russell 3000 Index, marking a milestone for its rare disease therapeutics. The company is included in the annual Russell US Indexes reconstitution, effective July 1, 2024, with $10.5 trillion in assets benchmarked against the Russell indexes. Soleno’s lead candidate, DCCR tablets for Prader-Willi syndrome, has completed its Phase 3 development program. FTSE Russell, a global provider of benchmarking and analytics, wholly owned by London Stock Exchange Group, focuses on index design and governance following industry standards.
Soleno Therapeutics, Inc. is set to join the Russell 3000 Index, a major milestone reflecting progress with its lead candidate DCCR tablets for rare diseases. The annual Russell US Indexes reconstitution includes Soleno, effective July 1, 2024, with $10.5 trillion in assets benchmarked against the Russell indexes. Soleno’s focus on rare disease therapeutics, including DCCR tablets for Prader-Willi syndrome, demonstrates its commitment to advancing novel treatments. FTSE Russell, a global provider of benchmarking and analytics wholly owned by London Stock Exchange Group, emphasizes index design and governance following industry standards.
Read more at GlobeNewswire: Soleno Therapeutics Set to Join Russell 3000® Index